Premium
Vitamin D metabolism in myeloma
Author(s) -
LawsonMatthew Peter,
Clayton Jill,
GuillandCumming Diane,
Yates Ashley,
Preston Eric,
Greaves Michael,
Kanis John A.
Publication year - 1989
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1989.tb00220.x
Subject(s) - hypercalcaemia , medicine , vitamin d and neurology , multiple myeloma , calcitriol , endocrinology , metabolism , bone remodeling , renal function , vitamin , calcium
Summary. We measured serum concentrations of vitamin D metabolites in 27 patients with myeloma, 16 of whom were hypercalcaemic. Serum values were compared with values from normal controls. Serum concentrations of calcitriol (1,25‐dihydroxyvitamin D; 1,25(OH) 2 D 3 ) were decreased in both hyper‐ and normocalcaemic patients, but more markedly so in hypercalcaemia. These findings were not solely due to impaired renal function nor due to an inadequate supply of 25‐hydroxyvitamin D, and in hypercalcaemic patients were reversed by diphosphonate treatment. We conclude that hypercalcaemia in myeloma is not mediated by abnormalities in vitamin D metabolism. Decreased serum concentrations of 1,25(OH) 2 D 3 may adversely affect both skeletal and tumour metabolism.